|
|
|
|
|
Sessions of Interest for the Upcoming 2021 Annual Meeting
|
|
|
|
|
|
| The Evolving Landscape of Advanced Prostate Cancer Treatment: A Guidelines and Case-Based Discussion - 0830-1700
|
|
|
|
|
|
Identification of High-Risk Disease and Initial Management of Biochemical Recurrence
Presented By: Stephen A. Boorjian, MD
|
|
|
|
|
Imaging of Advanced Prostate Cancer and Impact on Cancer Management
Presented By: Kelly L. Stratton, MD
|
|
|
|
|
M0 CRPC: Treatment Options and Goals of Therapy
Presented By: Michael S. Cookson, MD,MHA
|
|
|
|
|
Manipulating the Androgen Axis: New Agents in mHSPC and CRPC
Presented By: David F. Jarrard, MD
|
|
|
|
|
Genetic Testing in Advanced Prostate Cancer
Presented By: Leonard G. Gomella, MD, FACS
|
|
|
|
|
Bone Health and Radionuclide Therapy
Presented By: Stephen A. Boorjian, MD
|
|
|
|
|
Role of Immunotherapy and PARP Inhibitors
Presented By: Deborah R. Kaye, MD, MS
|
|
|
|
|
Role of Chemotherapy, Treatment Sequencing in mCRPC and Future Directions
Presented By: Joshua M. Lang, MD, MS
|
|
|
|
|
|
|
|
|
|
|
AUA Guidelines: Advanced Prostate Cancer
Presented By: William Lowrance, MD
|
|
|
|
|
State-of-the-art Lecture: First and Second Line Therapy in Advanced and Metastatic Bladder Cancer: A Changing Paradigm
Presented By: Cora Sternberg, MD
|
|
|
|
|
|
|
AUA Guideline Amendment: Muscle Invasive Bladder Cancer/Non-Muscle Invasive Bladder Cancer
Presented By: James McKiernan, MD
|
|
|
|
|
State-of-the-art Lecture: Personalized Medicine in the Management of Prostate Cancer Across the Patient Care Continuum
Presented By: Brian Chapin, MD
|
|
|
|
|
|
|
|
|
|
|
Ramon Guiteras Lecture: Three Decades of Bladder Cancer Treatment: Progress and Promise
Presented By: Eila Skinner, MDS
|
|
|
|
|
Confederacion Americana de Urologia (CAU) Lecture: Penile Cancer: Controversies and Challenges
Presented By: Alejandro Rodriguez, MD
|
|
|
|
|
| MP24: Prostate Cancer: Advanced (including Drug Therapy) II - 0845-1000
|
|
|
|
|
|
|
|
MP24-05: Long-Term Follow-Up and Prognostic Factor Analysis in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Who Receive Prostate-Specific Membrane Antigen (PSMA)-Targeted Lutetium-177 (177Lu),
Presented By: Alejandro Rodriguez, MD
MP24-07: Relugolix vs Leuprolide Effects on Castration Resistance-Free Survival from the Phase 3 HERO Study in Men with Advanced Prostate Cancer
Presented By: Fred Saad, MD, FRCS
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| PSMA-Targeted PET Imaging and Interpretation: What Urologists Need to Know - 0900-1030 |
|
|
|
|
|
PSMA-Targeted PET Imaging and Interpretation: What Urologists Need to Know, Steven Rowe
Presented By: Michael Gorin, MD
|
|
|
|
|
| LBA02: Late-breaking Abstract II - Malignant - 1530-1730 |
|
|
|
|
|
LBA02-01: Persistent Deficiencies in the Measurement and Reporting of Tobacco use in Contemporary Genitourinary Oncology Clinical Trials
Presented By: Calvin Zhao, MD
|
|
|
|
|
LBA02-02: Initial Results from a Phase 1/2 Trial of Large Surface Area Microparticle Docetaxel for High-Risk Non-Muscle Invasive Bladder Cancer
Presented By: Max Kates, MD
|
|
|
|
|
LBA02-03: A Phase II Randomized Clinical Trial Of Yoga In Men With Prostate Cancer
Presented By: Dharam Kaushik, MD
|
|
|
|
|
LBA02-04: Novel Weekly Immunotherapy Dosing with Avelumab Tolerated During Bacillus Calmette-Guerin Induction Therapy: Initial Results of the ABC Trial
Presented By: Kelly Stratton, MD
|
|
|
|
|
LBA02-05: NAXIVA - A Phase II Neoadjuvant Study of Axitinib for Reducing Extent of Venous Tumor Thrombus in Clear Cell Renal Cell Cancer with Venous Invasion: Translational Results
Presented By: Sarah Welsh, MD
|
|
|
|
|
LBA02-06: Prospective Evaluation of 18F-DCFPyL PET/CT in Biochemically Recurrent Prostate Cancer: analysis of 18F-DCFPyL uptake in possible extra-pelvic oligometastases
Presented By: Andrei Iagaru, MD, FACNM
|
|
|
|
|
LBA02-07: Prospective Study of 68Ga-RM2 PET/MRI in Patients with Biochemically Recurrent Prostate Cancer and Negative Conventional Imaging
Presented By: Andrei Iagaru, MD, FACNM
|
|
|
|
|
LBA02-08: The IMPROVE Trial: Surgical Technique Remains the Most Important Factor Associated With Recovery of Urinary Continence After Radical Prostatectomy
Presented By: Rafael Sanchez-Salas, MD
|
|
|
|
|
LBA02-09: A High Through-Put Test Interrogating 442 Small Non-Coding RNAs (sncRNA) Extracted From Urine Exosomes Accurately Identifies and Stratifies Prostate Cancer into Low-, Intermediate- or High-Risk Disease
Presented By: Laurence Klotz, MD, FRCSC
|
|
|
|
|
LBA02-10: Long-Term Recurrence -Free Survival Following UGN-101 Treatment for Low-Grade Upper Tract Urothelial Carcinoma
Presented By: Karim Chamie, MD, MSHS
|
|
|
|
|
LBA02-11: Masitinib Plus Docetaxel as First-Line Treatment of Metastatic Castrate Refractory Prostate Cancer: Results from Study AB12003
Presented By: Michel Pavic, MD
|
|
|
|
|
LBA02-12: MRI-guided Focused Ultrasound (MRgFUS) Focal Therapy for Intermediate-Risk Prostate Cancer: Final Results of a Phase IIb Multicenter Study
Presented By: Behfar Ehdaie, MD, MPH
|
|
|
|
|
|
|
|
|
| PD55: Bladder Cancer: Invasive IV - 0700-0900 |
|
|
|
|
|
PD55-01: Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma in the JAVELIN Bladder 100 trial: Subgroup Analysis by Duration of Treatment-Free Interval From End of Chemotherapy to Start of Maintenance
Presented By: Shilpa Gupta, MD
|
|
|
|
|
|
|
|
|
|
|
|
Written Conference Summaries by Leading Urologists and Uro-Oncologists
|
|
|
|
|
|
Christopher Wallis, MD, Ph.D.
Assistant Professor of Urology in the Department of Surgery at the University of Toronto. He obtained his Doctor of Medicine from the University of British Columbia, his Doctor of Philosophy in Clinical Epidemiology & Health Care Research from the Institute of Health Policy, Management & Evaluation at the University of Toronto, and completed his clinical residency in Urology at the University of Toronto affiliated hospitals.
|
|
|
|
|
|
|
|
|
|
|
Zachary Klaassen, MD, MSc
Assistant Professor of Urology, Georgia Cancer Center, Augusta University/Medical College of Georgia. He attended medical school at St. George's University in Grenada, followed by clinical rotations and a research fellowship in the metro New York area. After completing his Urology residency in Augusta, he spent two years in Toronto as a Society of Urologic Oncology fellow, also obtaining a Masters of Science degree from the University of Toronto in Clinical Epidemiology. |
|
|
|
|
|
|
|
|
|
|
|
Thenappan Chandrasekar MD
Assistant Professor and Director of Abington-Jefferson Urology, He attended medical school at Sidney Kimmel Medical College at Thomas Jefferson University, with an internship and residency at University of California/Davis Medical Center. He also spent time as a fellow in Urologic Oncology at the University of Toronto and Endourology at Thomas Jefferson University Hospital.
|
|
|
|
|
|
|
|
|
|
|
